AXIOS September 14, 2023
Caitlin Owens

The legal challenges to President Biden’s drug price negotiation law could be on a collision course with the 2024 election.

Why it matters: Should the Medicare negotiation program survive its first courtroom showdown tomorrow, analysts say drug companies challenging the law could still have several chances to stop the program before next year’s election — which could undercut Biden’s ability to campaign on his victory over Big Pharma.

Driving the news: A federal judge in Ohio on Friday will hear oral arguments on the U.S. Chamber of Commerce’s request to halt the program before Oct. 1, the deadline for companies to agree to Medicare negotiations on the first 10 selected drugs.

The Biden administration and the Chamber are expected...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Congress / White House, Govt Agencies, Insurance, Medicare, Pharma, Pharma / Biotech
Related Articles:
Biden administration proposes Medicare coverage for weight loss drugs: 10 things to know
Proposed Coverage of Anti-Obesity Drugs in Medicare and Medicaid Would Expand Access to Millions of People with Obesity
Prior authorizations, pharmacy transparency, vertical integration all part of the Medicare 2026 rule
Medicare and Medicaid would cover Ozempic, Wegovy under new Biden rule
New Proposal Aims to Expand Medicaid and Medicare Coverage for Obesity Drugs

Share This Article